Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR)
Public ClinicalTrials.gov record NCT01463423. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Trial of Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A research study of a procedure to treating lung cancer with focused radiation called Stereotactic Ablative Radiotherapy (SABR). The purpose of this study is to evaluate the effectiveness of individualizing the dose of radiation used to treat lung tumors with SABR based on tumor-specific factors. While recent research has identified SABR as a promising method to increase local control (LC) of lung cancer, further research has indicated that tumor volume is a prognostic factor, with increased size/volume of tumor being associated with poorer outcomes. This study explores if a volume-adapted strategy for the radiologic exposure (dose) will improve efficacy in larger tumors (ie, \> 10 cc). This is a study of the procedure stereotactic ablative radiotherapy (SABR). It is not a study of a specific drug or device.
Study identification
- NCT ID
- NCT01463423
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 256 participants
Conditions and interventions
Conditions
Interventions
- iSABR, 25 Gray in 1 fraction for small peripheral tumors Radiation
- iSABR, 50 Gray in 4 fractions for medium peripheral tumors Radiation
- iSABR, 54 Gray in 3 fractions for large peripheral tumors Radiation
- iSABR, 40 Gray in 4 fractions for small central tumors Radiation
- iSABR, 50 Gray in 4 fractions for medium central tumors Radiation
- iSABR, 60 Gray in 8 fractions for large central tumors Radiation
Radiation
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 20, 2011
- Primary completion
- Jan 1, 2020
- Completion
- Feb 6, 2022
- Last update posted
- Dec 18, 2024
2011 – 2022
United States locations
- U.S. sites
- 2
- U.S. states
- 2
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Stanford University Cancer Institute | Stanford | California | 94305 | — |
| Swedish Cancer Institute | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01463423, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 18, 2024 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01463423 live on ClinicalTrials.gov.